The Commissioner of the Food and Drug Administration (FDA) (Kessler, 1994) advocated for a future role of the FDA in the regulation of tobacco, comparing nicotine delivery devices to drugs under that agency's jurisdiction. Upon Presidential invitation, tobacco free youth selected from the American Lung Association's Smoke Free Class of 2000 program were brought to the White House in support of the FDA's assertion that tobacco use is a pediatric disease. At the level of state action, cigarette taxes were raised, clean indoor air laws were passed, and "sting" operations were conducted to curb illegal sales of tobacco products to youth. The states of Minnesota, Mississippi, Florida, and Texas sued and settled with the tobacco manufacturing industry in an effort to recoup billions of dollars in medical costs from treating smoking related illnesses. Individual activists, watchdog public groups, the media, and scientists joined all branches and levels of government in exposing the industry'S record profits, manipulation of nicotine levels, suppression of internal documents, and deceitful marketing campaigns.
Despite failure of the United States Senate to pass comprehensive tobacco control legislation in 1997, the threat of individual state lawsuits convinced the embattled U.S. tobacco industry to settle in 1998 with the Attorneys General of the remaining 46 states to avoid potential bankruptcy from impending litigation (National Association of Attorneys General, 1998) . The resultant negotiations, known as the Master Settlement Agreement (MSA), obligated the industry to disclose its past behaviors, make payments totaling hundreds of billions of dollars to the states during a 25 year period, and to refrain from marketing to youth or opposing restrictive youth related tobacco legislation. The MSA, or any other strategy primarily addressing tobacco use among youth, did little to advance the likelihood of tobacco's disappearance as a major health issue in the next several decades, or at any time in the foreseeable future. It did, however, accomplish change, which permanently energized the tobacco control movement, as witnessed by efforts to globalize the effort (Bartecchi, 1995; Simpson, 1999) .
Opportunities in many areas await occupational health nurses and others who wish to participate (Caplan, 1995) . There are pressing needs for delivery of treatment services to adult tobacco users. This includes the workplace where, despite improvements, much remains to be accomplished (National Cancer Institute, 1999) . It is important to emphasize strategies that improve identification, motivation, and treatment of nicotine addiction of 48 million current adult smokers who pose a risk to themselves and to others. Vast numbers of tobacco users will benefit, as well as the general population and those with whom tobacco users have close interactions. Larger community and societal needs, including advocacy, remain highly appropriate activities for occupational health nurses.
Ambitious plans exist to attain the goal of only 12% adult smokers in the population by 2010 (Green, 2(00) . Annual funding approximating 100 million dollars for the Centers for Disease Control and Prevention (CDC) Office of Smoking and Health, with additional monies from federal, state, local, and private sources, is currently available to facilitate maintenance and development of core tobacco control programs (Redhead, 1999) . Health care providers are important stakeholders in these efforts and must be willing and able to take on multiple responsibilities. Many issues can be transformed into the opportunities addressed in this article.
KEY CONCERNS ABOUT TOBACCO Tobacco as a Cause of Illness and Premature Death
Smoking results in 434,000 deaths per year in the United States alone and creates direct medical expenditures of $50 billion, plus an estimated $47 billion in indirect costs such as lost productivity (American Lung Association [ALA] , 2(00). Tobacco use ranks number one among preventable causes of death, extracting a cumulative toll of nearly 20% of all deaths in the United States (McGinnis, 1993) . Smoking causes 80% to 90% of deaths related to lung cancer, nearly 50% of heart disease deaths, and 80% to 85% of the mortality from chronic obstructive pulmonary disease (American Thoracic Society, 1996; Villablanca, 2(00) . It has strong links to deaths from other cancers, other cardiovascular diseases, and diabetes.
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Source, Uptake, and Actions of Nicotine Commercially grown tobacco is the primary source of nicotine in the world. Two species of plants, Nicotiana Tabacum and Nicotiana Rustica, are grown in dozens of countries and contain 2% to 8% nicotine content. Nicotine is a potent and toxic chemical. A drop of pure nicotine (approximately 70 mg), when rapidly consumed by an adult (i.e., by intravenous injection), would likely be a fatal dose. On the other hand, Benowitz (1984) demonstrated that cigarette smokers absorbed an average of 37 mg of nicotine per day, or approximately 1 mg per cigarette.
Nicotine from pipes, cigars, and chewing tobacco is absorbed through mucosal surfaces of the oral cavity. It is primarily uncharged and therefore more freely permeable in the alkaline conditions of the smoke or saliva bathing that site. The acid pH of cigarette smoke, conversely, leaves more of the nicotine in a positively charged form, hindering uptake (Benowitz, 1996) . Deep inhalation is the key compensating factor, allowing extensive nicotine uptake throughout the lung. The capillary lined alveoli in that organ form a highly absorptive surface for nicotine adhered onto fine smoke particles. When absorbed from the lungs of a smoker, nicotine reaches the brain in approximately 10 seconds, faster than through an intravenous injection or mucosal absorption. Physiological effects may occur after a single puff and peak within the first minute of self administration. With smoking, each puff presents the brain with favorable concentrations of nicotine, but soon thereafter another inhalation must occur as nicotine is rapidly distributed to peripheral tissues and away from the brain (National Institute on Drug Abuse, 1998). Half of a nicotine dose is metabolized in only 2 hours by the liver, lungs, and other organs. A plateau in blood levels occurs during the first 6 to 8 hours of smoking as metabolism and redistribution cancel the tobacco user's additional intake. Overnight, nicotine levels diminish once again. However, there is still enough nicotine in the blood of smokers in the morning to predict biological activity at various targets (Benowitz, 1999a) .
The physiological and pharmacological effects of nicotine largely are a reflection of its ability to function as a neuroactive agonistic chemical usurping the actions of the normal neurotransmitter acetylcholine. Nicotine binds to specialized receptors found in at least seven key areas of the brain, ganglia of the parasympathetic and sympathetic arms of the autonomic nervous system, and at the neuromuscular junction. The binding of the agonist to various forms of the nicotinic receptor allows an opening of ionic gates, which changes the permeability of ions such as sodium and potassium. Subsequent actions may include generation of an electrical impulse for propagation along the neuronal axon, further release of neurotransmitters at nerve endings and synapses, or stimulation of muscle through the excitation contraction coupling process.
By mimicking the effect of acetylcholine to stimulate the brain's dopaminergic system, nicotine produces euphoric effects in the brain, leading to the reward or satisfaction experienced by the tobacco user (Blum, 1996) . Other positive reinforcements mediated in the brain by nicotine include relaxation, reduction of stress, mood modulation, and higher vigilance (Benowitz, 1999b) . Activation of the hypothalarnic-pituitary-adrenal axis and other pathways causes release of hormones (e.g., serotonin, vasopressin, growth hormone, corticotropin, cortisol, prolactin, endorphins) , which are also related to positive reinforcement (Benowitz, 1999a; Pomerleau, 1984) ( Figure 1 ). Overall behavioral changes following nicotine intake are not always excitation or stimulation, suggested by the decreased anxiety and aggression in tobacco users. Concomitant with a decrease in anxiety, there may be a reduction in stress induced eating.
Peripheral sites of action include the adrenal cortex, cardiovascular system, gastrointestinal system, and skeletal motor system. Cardiovascular effects are especially noteworthy because the workload of the heart is increased by a higher heart rate and blood pressure. Nicotine is implicated in alterations of the body's metabolism of fat and may promote atherosclerosis. The brain may manifest higher uptake and use of glucose, indicative of higher neuronal activity. Metabolic rate is significantly increased and appetite is somewhat suppressed by nicotine, accounting for the typical 5 to 10 pound weight gain upon nicotine abstinence.
Nicotine Addiction
Nicotine use meets the criteria of the American Psychiatric Association (2000) for causing chemical dependence (Table 1 ). The addictive potential of nicotine, like that of opiates, involves both physical and psychological changes. The daily pattern of use becomes compulsive, repetitive, and highly controlled (Fiester, 1997) . Tobacco users, primarily smokers, are able to rapidly experience the positive reinforcements and avoid the negative reinforcements of even short term withdrawal by repeated dosing. With smoking, transient peaks of the levels of nicotine in the blood are accompanied by a substantial decline after a cigarette is extinguished. Sufficient time is thus allowed to resensitize brain nicotinic receptors and diminish any outward tolerance apparent to the smoker.
When abstaining from or diminishing their consumption, smokers and other tobacco users may exhibit nervousness, restlessness, irritability, anxiety, and diffi- culty in concentration and cognition. The prior action of nicotine in the relief of stress can transform into an important cause of stress in its absence. If a tobacco user has the additional tendency to consume other addictive or mood altering substances, potential to abuse these agents for self medication to mask stress is a significant concern.
Other Harmful Ingredients in Cigarette Smoke
In addition to nicotine content, cigarettes are rated for their tar content. Tobacco tar is an oily, pigmented residue left behind when moisture evaporates from combusted tobacco. It has known cancer producing potential. The Federal Trade Commission uses smoking machines to test cigarettes for both their nicotine and tar content. There is criticism that the resultant numbers do not adequately reflect the amount introduced into the body of smokers (Hoffmann, 1997) . While nicotine and tar have always occupied center stage, great concern exists over the multitude of other chemicals in tobacco introduced during the growing and processing of tobacco. A finished tobacco product, which is burned, contains approximately 4,000 distinct chemicals in two phases, gaseous and particulate (USDHHS, 1989) . When receiving a dose of nicotine from tobacco smoke, the smoker experiences an obligatory uptake of highly reactive, poisonous, and otherwise toxic chemicals. Among the most notable toxins are oxidants and metabolic poisons produced during combustion. Radioactivity, heavy metals, and pesticides may accumulate within the leaf of tobacco during the growing process. In many circumstances, it is the health consequences of the other ingredients and contaminants of tobacco, as opposed to the toxicity of nicotine, per se, which cause concerns over the harmful nature of tobacco smoke.
Prevalence of Smoking
In 1965, at the height of the smoking epidemic in the United States, smokers comprised 52% of the adult male population and 32% of the adult female population (Fiore, The same or a closely related substance is taken to for nicotine relieve or avoid withdrawal symptoms 3 Nicotine is often taken in larger amounts or over a longer period than was intended 4
There is a persistent desire or unsuccessful effort to cut down or control nicotine use 5 A great deal of time is spent in activities necessary to obtain nicotine or recover from its effects 6 Important social, occupational, or recreational activities are given up or reduced because of nicotine use 7 Nicotine use is continued despite knowledge of having had a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by nicotine 8 Characteristic withdrawal symptoms 9
Nicotine often taken to relieve or avoid withdrawal symptoms Nicotine dependence: a maladaptive pattern of nicotine use, leading to clinically significant impairment or distress, as manifested by three or more of the above occurring at any time in the same 12 month period.
Reprinted with modification from: American Psychiatric Association (2000) .
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). Nationwide, considerable progress was made in lowering smoking rates near the end of the century to less than 25% of adults. However, the rate of decline in smoking slowed dramatically in the 1980s and 1990s for men and women. The current adult smoking population in the United States is nearly equally men (28%) and women (22%). Tobacco use from smokeless forms or smoking pipes and cigars continues to plague society, although the rate of use is considerably lower. Smokeless tobacco, which is popular among athletes and young men, especially in rural areas of the Midwest and Southeast, addicts 5% of adults and 10% of young boys (Bell, 2000; National Cancer Institute, 1992; Severson, 1999) . Public health concerns over cigar smoking were recently summarized by the U.S. Surgeon General (National Cancer Institute, 1998) on the basis of unit production of toxins, disproportionate contribution to ETS, and growing popularity among younger and more affluent segments of the population.
Special Populations
Ernster (2000) recently reviewed unique issues related to smoking among women, including osteoporosis, 246 specific cancers, and untoward outcomes of pregnancy (Table 2) . Smoking speeds the onset of menopause by I to 2 years and, in tandem with use of oral contraceptives in women older than age 35, increases risk of myocardial infarction and stroke due to thrombosis and thromboembolism (Castelli, 1999) . In addition, women who smoke tend to be more plagued by depression than men who smoke, have greater concern over weight gain, and respond less favorably to the currently available pharmacological therapies (Fiore, 2000) .
In the past decade, underage tobacco use has surfaced as a major social and health care issue because initiation and addiction to smoking is thought to commence during adolescence (i.e., by their 18th birthday) in 90% of tobacco users (Lynch, 1994) . Both boys and girls have increasingly experimented with cigars, apparently unaware of the considerable health risk imposed (Iribaren, 1999; National Cancer Institute, 1998) . In the rural areas of six Southeastern states responsible for growing 94% of United States tobacco crops (i.e., Kentucky, North Carolina, Tennessee, South Carolina, Virginia, and Georgia), tobacco is an essential part of the agricultural commodity mix. These states are also sites of high rates of youth and adult smoking and chewing.
Throughout the military, both men and women exhibit exceptionally high rates of smoking. Among racial minorities in 1997, 34% of adult Native Americans smoked, followed by African Americans, Hispanics, and Asian Americans and Pacific Islanders at 27%, 20%, and 17%, respectively (USDHHS, 1998) . Except for pipe and cigar products, most forms of tobacco are consumed by those with lower education and income (CDC, 2000a) . Ironically, colleges and universities have been a site of increased tobacco use, despite having adopted restrictive smoking policies (Rigotti, 2000) .
Environmental Tobacco Smoke
The generation of ETS from burning tobacco poses major additional hazards (National Cancer Institute, 1999) (Table 3) , as it is a major contributor to indoor air pollution in the workplace, public and private buildings, and residential dwellings. Because people spend approximately 90% of their time indoors, it is not surprising that approximately 3000 lung cancer deaths and 30,000 to 50,000 cardiac deaths per year in the United States are attributable to ETS (National Cancer Institute, 2000) . In addition, inhalation of ETS contributes greatly to the burden of respiratory disease in children, including asthma and other reactive airways disorders (ALA, 2000) . The ETS consists of smoke from the smoldering tobacco and that exhaled by the smoker. These are known as sidestream and mainstream smoke, respectively. The inhaled smoke produced as air is drawn through the length of the burning cigarette achieves more complete combustion and thereby a lower concentration of some smoke byproducts when compared to sidestream smoke from the smoldering end of the cigarette (National Research Council, 1986) (Table 4) .
Tobacco Consumption and ETS Exposure in the Workplace
A number of hazardous materials in the workplace present a serious health threat when combined with smoking: dusts (e.g., coal, grain, silica, cotton), welding materials, asbestos, petrochemicals, aromatic amines, pesticides, and ionizing radiation. It was mentioned earlier that decreased productivity, including frank absenteeism, contributes to cumulative costs of smoking to society. Total cost of tobacco use to businesses, which may exceed $5,000 per employee per year, also includes: • Health insurance and life insurance costs and claims. • Workers' compensation and occupational health payments.
• Accidents and fires (plus related insurance costs). MAY 2001, VOL. 49, NO.5 From: Ernster (2000) . Reprinted with permission.
• Property damage (plus related insurance costs).
• Smoke pollution (plus increased cleaning and maintenance costs).
• Illness and discomfort among nonsmokers exposed to passive smoke (USDHHS, 1996) .
States with the strictest clean indoor air laws, such as California, have experienced an impressive reduction in worker exposures and concomitantly have experienced improvement in worker health. Several factors influence the extent to which smoke free workplace policies are adopted. Larger employers are more likely to adopt restrictive smoking policies, compared to smaller (fewer than 100 workers) employers. Hospitality, service, and 
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blue collar workplaces in manufacturing and processing industries remain behind in the trend toward smoke free environments (National Cancer Institute, 2000) .
BUILDING CONSENSUS ON OPERATIONAL STRATEGIES TO REDUCE TOBACCO RELATED DISEASE, DISABILITY, AND DEATH
A flurry of recent reports, including the U.S. Surgeon General's Report (USDHHS, 2000) and CDC Best Practices Guidelines (CDC, 1999) have focused on treatment of nicotine addiction as a part of the overall agenda to minimize tobacco use. Approximately 70% of current smokers have said they would like to quit. However, encouraging their cessation attempts and providing access to efficacious treatment present enormous logistical challenges. The benefit would be that several thousand lives could be saved each year. When factored on the basis of dollars spent per life saved, analysts suggest that nicotine dependency treatments are more economical than widely adopted harm reduction measures such as mammography, prostate examination, and long term use of cholesterol lowering drugs (Tengs, 1995) .
Addressing potential gains for society and the tobacco user, the Agency for Healthcare Research and Quality (AHRQ) (Fiore, 2000) recently updated guidelines for treatment of tobacco dependence in all tobacco users. Through a series of eight recommendations (Table 5) , it addresses tobacco dependence as a chronic condition and provides a cohesive, comprehensive framework for institutionalizing treatment within the health care system. Importantly, insurers and purchasers are given a central role (e.g., recommendations three and eight in Table 5 ), so issues such as reimbursement, widespread access, and coordination of care among providers are considered.
Identification of tobacco use by physicians, dentists, physician assistants, nurse practitioners, nurses, physical and occupational therapists, pharmacists, and other clinicians is a necessary first step in treatment of tobacco use and dependence. Current users are addressed through the following two complementary strategies: • Provide brief interventions to increase motivation to quit among those unwilling to try to quit tobacco. • Provide proven treatments for the 70% of tobacco users wanting to quit or seriously curtail their use.
Screening improvements are needed over the current status quo, as it is estimated that one third of current smokers report not being asked about their smoking history. The AHRQ (Fiore, 2000) steps recommended after this universal intervention (i.e., asking) include the following: • Provide advice to quit. In a clear, strong, and personalized manner every tobacco user should be encouraged to quit. t4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone.
From: National Research Council (1986).
• Assess willingness to make a quit attempt. Determine whether the tobacco user is willing to make a quit attempt.
• Assist in quit attempt. For the individual willing to make a quit attempt, counseling and pharmacotherapyshould be used. MAY 2001, VOL. 49, NO.5 • Arrange follow up. A follow up contact should be scheduled, preferably within a week after the quit date. Use of a tool, such as the Fagerstrom Test for Nicotine Dependence, helps determine the severity of nicotine RECOMMENDATION 2: Because effective tobacco dependence treatments are available, every patient who uses tobacco should be offered at least one of these treatments:
• Patients willing to try to quit tobacco use should be provided treatments identified as effective in this guideline . • Patients unwilling to try to quit tobacco use should be provided a brief intervention designed to increase their motivation to quit.
RECOMMENDATION 3: It is essential that clinicians and health care delivery systems (including administrators, insurers , and purchasers) institutionalize the cons istent identification, documentation, and treatment of every tobacco user seen in a health care setting.
RECOMMENDATION 4: Brief tobacco dependence treatment is effective, and every patient who uses tobacco should be offered at least brief treatment.
RECOMMENDATION 5: There is a strong dose response relation between the intensity of tobacco dependence counseling and its effectiveness. Treatments involving person to person contact (via individual, group, or proactive telephone counseling) are consistently effective, and their effectiveness increases with treatment intensity (e.g., minutes of contact).
RECOMMENDATION 6: Three types of counseling and behavioral therap ies were found to be especially effective and should be used with all patients attempt ing tobacco cessation :
• Provision of practical counseling (problem solving and skills training).
From: Fiore (2000) .
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(RECOMMENDATION 6, continued)
• Help in securing social support outside of treatment (extratreatment social support) . • Provision of social support as part of treatment (intratreatment social support) . As such , insurers and purchasers should ensure that:
• All insurance plans include as a reimbursed benefit the counseling and pharmacotherapeutic treatments identified as effective in this guideline . • Clinicians are reimbursed for providing tobacco dependence treatment just as they are reimbursed for treating other chronic conditions. Reprinted with permission from: Fagerstrom (1989) .
Answers
Within 30 dependency (Fagerstrom, 1989) (Table 6 ). However, more importantly, the assessment step builds a foundation of trust and anticipates different implementation strategies variably tailored to each person. It provides an opportunity to reach out to the tobacco user, while respecting the potential mental and physical anguish one faces during treatment. The tobacco user may fail to equate intensive interventions, such as group counseling, with their best interest and express indifference or outright resistance. In such cases, providing access to self help manuals and pharmacotherapy represents a negotiable middle ground approach, albeit less successful than when full blown commitment of the individual is obtained. Identification of the client as a member of a special population (e.g., minors, pregnant, physically or emotionally vulnerable) can be the basis of providing additional counseling or a specific rationale for selecting, postponing, or avoiding any or all means of pharmacotherapy. When providing assistance during preparation to quit, the topics to be discussed should invariably include setting a quit date, establishing social support (e.g., family, friends, coworkers), optimum use of clinical resources, dealing with other smokers, and other challenges (e.g., encountering tobacco products and alcohol). A thorough discussion of nicotine withdrawal symptoms and benefits of treatment MAY 2001, VOL. 49, NO.5 is vital, such as those depicted in Figure 2 (CDC, 2000b) . It is always wise, when feasible, to use regular and supplementary materials appropriate to the individual's age, racial, educational, and cultural status. For web users, the Internet sites of government agencies and health nonprofits are replete with up to date, scientifically sound self treatment information which can be downloaded free of charge.
The arrangement of follow up contact, ideally within the first week and first month of quitting, is highly recommended. Whether in person or by phone, both interventional methods provide the opportunity to recognize and congratulate success, offer additional support, and provide advice. The in person visit allows the further use of biochemical or physiological monitoring of successful abstinence, such as urinary cotinine or exhaled carbon monoxide (CO) levels (inexpensive CO monitors are now used frequently in tobacco treatment programs). Other considerations at the follow up visit are: • Use a discussion of circumstances surrounding any episodes of tobacco use as valuable learning experiences. • Encourage renewed commitment to total abstinence. • Discuss progress or difficulties with use of pharmacotherapy.
• Establish the nature of any past, current, or anticipated problems and challenges.
Stroke risk reduced to that of "NS" 5 to 15 years after quitting.
Cancers of the Mouth, Throat, and Esophagus risk halved compared to "CS" 5 years after quitting.
Cancer of the Larynx risk reduced compared to "CS" after quitting.
-----11---.,.-Coronary Heart Disease excess risk halved compared to "CS" 1 ye-=-ar::r------tf-after quitting; risk returns to that of "NS" after 15 years.
Chronic Obstructive Pulmonary
Disease risk of death reduced compared to "CS" after long-term quitting.
Lung Cancer risk as much as halved compared to "CS" 10 years after quitting.
Pancreatic Cancer risk reduced compared to "CS" 10 years after quitting.
Ulcer risk reduced compared to _ _---' "CS" after quitting.
Bladder Cancer risk halved com-_ _p ared to "CS" a few years after quitting.
"---_ _ Peripheral Artery Disease riskr educed compared to "CS" after quitting.
CS = Cigarette smoker NS = Non-smoker
Cervical Cancer risk reduced compared to "CS" a few years after quitting.
Low Blrthweight Baby risk reduced to that of "NS" for women who quit before pregnancy or during first trimester.
Figure 2. Beneficial effects of smoking cessation. From: Centers for Disease Control and Prevention (2000b).
Partial successes or outright failures are commonplace, but this fact should not deter the individual or health care provider from making additional attempts. Higher rates of recidivism are often seen with those exhibiting high nicotine dependence, psychiatric comorbidity (e.g., depression, schizophrenia, alcoholism, other chemical dependency), or experiencing high levels of stress. Self reporting of greater than a pack per day smoking history or smoking within 30 minutes of daily awakening (through the Fagerstrom Test for Nicotine Dependence questionnaire) is typically associated with low abstinence rates. Severe nicotine dependence may be inferred from current and previous withdrawal symptoms.
While the health care provider may feel stifled and unappreciated by the unwillingness of some individuals to make a quit attempt, each visit with such individuals should include a motivational intervention providing education and reassurance. The success of such encoun-ters increases when conducted in an empathetic, congenial manner, to include topics such as: • Personal relevance of quitting to the tobacco user. • Short term, long term, and environmental risks. • Rewards.
• Typical barriers to quitting. • Repeated encouragement using successful quitters as examples (Fiore, 2000) .
Additional benefits may accrue when tobacco users feel their options and self efficacy are promoted.
The Stages of Change Model developed by Prochaska (1983) is one of the several theoretical models on which to base health promotion interventions. A major value of the Stages of Change Model in treatment of nicotine dependency is the focus on small, step wise achievements (Le., a longitudinal process of striving to achieve the goal of future total abstinence). A person's readiness to change, or make reasonable attempts to change, in seeking a tobacco Used with permission and modified from: Prochazka (2000) free lifestyle is required early in treatment. In the treatment of tobacco dependency, for which it was originally developed, individual progress and setbacks are explained by the model in terms of five stages: precontemplation, contemplation, preparation, action, and maintenance. The process of becoming and staying tobacco free when applying the Stages of Change Model is shown in Table 7 . Individuals are in the precontemplation stage when they lack awareness of any major relevance of tobacco in their existence, lack a sense of responsibility for their actions, or otherwise have strong reasons to ignore or minimize the advice they have received. It also predicts that previous tobacco users often relapse over time, despite temporary success, because their healthier behavior cannot be sustained without continued vigilance and discipline. Between the precontemplation stage and relapse are contemplation, preparation, action, and maintenance. These actually represent the stages during which beneficial interventions are accepted, decided on, and ultimately acted on. They represent a succession of treatment steps for the tobacco user, the attainment of which may require the health care provider's close assistance in providing critical detail and thoroughness. All of the stages of change are reversible because a tobacco user often exhibits flagging MAY 2001, VOL. 49, NO.5 interest in setting a quit date or initiating preliminary action, such as enrolling in a smoking cessation program. The gains made via entry and participation in a treatment program also may be temporary. Circumstances that may translate into reverting back to an earlier stage in the quit process include: motivation begins to wane, prior decisions are second guessed or reneged, or actions are not reinforced through continual repetition.
Nicotine Replacement Therapy
Treatment of nicotine addiction consists of two separate components: dealing with withdrawal and combating habits or contributory social settings associated with tobacco use. Recognizable withdrawal symptoms from nicotine last from hours to weeks and present a potential barrier to successful abstinence. They include: restlessness, eating more than usual, anxiety or tension, impatience, irritability or anger, difficulty concentrating, excessive hunger, depression, disorientation, loss of energy or fatigue, dizziness, stomach or bowel problems, headaches, sweating, insomnia, heart palpitations, tremors, and cravings for tobacco products. Starting in 1984 with the availability of nicotine gum in the United States, there have been a number of nicotine replacement products marketed as over the Nicotine Polacrilex (nicotine gum)
Nicorette®
The term "gum" is misleading .
Although it actually is a gum like substance impregnated with small amounts of nicotine, nicotine gum is not chewed like regular gum. Instead, you chew it briefly and then "park" it between your cheek and gum. The nicotine is absorbed through the lining of the mouth.
Nicotine Nasal Spray
Nicotro r" NS (prescription required)
Delivers nicotine through the lining of the nose when you squirt it directly into each nostril.
Pros:
• Easy to use • Only needs to be applied once a day • Some available without a prescription • Few side effects Cons:
• Less flexible dosing • Slow onset of delivery • Mild skin rashes and irritation Pros:
• Convenient • Flexible dosing • Faster delivery of nicotine than the patches Cons:
• May be inappropriate for people with dental problems and those with temporomandibular joint (TMJ) syndrome • Cannot eat or drink while the medication is in your mouth • Frequent use during the day required to obtain adequate nicotine levels Pros:
• Flexible dosing can be used in response to stress or urges to smoke • Fastest delivery of nicotine of currently available products • Reduces cravings within minutes Cons:
• Nose and eye irritation is common , but usually disappears within 1 week. • Frequent use during the day required to obtain adequate nicotine levels
Comments and Limitations:
Patches vary in strengths and the length of time over which nicotine is delivered. Depending on the brand you use, may be be left on for anywhere from 16 to 24 hours. Some smokers who who use these products can stop them abruptly, while others prefer to reduce their dosage slowly.
Many people use this medication incorrectly. Most of the time the gum is in your mouth , it should be "parked" between your cheek and gum. Read package direct ions carefully for a full explanat ion.
To achieve greatest benefit, you generally should chew nine or more pieces per day.
Unlike nasal sprays used to relieve allergy symptoms, the nicotine spray is not meant to be sniffed. Rather, it is sprayed once into each nostril once or twice an hour. Take a deep breath , hold it, spray once into each nostril and exhale through the mouth. Ask your pharmacist for help in using the product correctly.
(Continued)
counter and prescription medications to alleviate symptoms and cravings of nicotine withdrawal (CDC, 2000c) . As each has been introduced, there has been an enthusiastic response, typically followed by a moderation of use.
Each type of nicotine replacement therapy (NRT) works when used properly, but none have been shown to be overwhelmingly effective when used alone. All are still considered first line therapy for nicotine dependency. Side 
Directions for Tobacco Users When Using First Line Pharmacotherapy for Treating Nicotine Dependency
Nicotine Inhaler Nicotro!® Inhaler (prescription required)
A plastic cylinder containing a cartridge that delivers nicotine when you puff on it. Although similar in appearance to a cigarette, the inhaler delivers nicotine into the mouth, not the lung, and enters the body much more slowly than the nicotine in cigarettes.
Non-nicotine medication
Zyban" (bupropion hydrochloride)
Sustained Release Tablets (prescription required)
Currently the only non-nicotine medication shown to be effective for quitting smoking. Treatment must be started at least 1 week before your target date.
• 
Comments Limitations:
This is the first medication to help quit smoking that is available in tablet form. Its primary role is to act on brain chemistry to bring about some of the same effects that nicotine has when people smoke. A small risk of seizure is associated with use of this medication. The main ingredient has been available for many years as a treatment for depression under the trade name Wellbutrin. However, it works well in people with no depression as an aid.
From: American Lung Association (1998) . Reprinted with permission. effect profiles and disadvantages or limitations have been noted (ALA, 1998) (Table 8 ). Immediate concern surrounding cardiovascular events in certain populations using NRT was dispelled after more post marketing data were obtained (Balfour, 2(00) . Different dosages and routes of administration are currently available. Nicotine gum is available in 2 mg and 4 mg doses for use during a normal treatment period of 2 to 3 months without prescription. The preferred dosage for heavier smokers is the nighttime is recommended for tobacco users who experience sleeping difficulties. When employed for the recommended 6 weeks with either constant or tapered strength of patches, a 1.6 fold (60% above control) increase in the odds of abstinence has been attained (Fiore, 2000) . Nicotine spray and nicotine inhaler are newer, novel means of self administration which have proven safe and efficacious. A major limitation is that both preparations are only available by prescription. As with all recently developed pharmacotherapies, fewer controlled studies are available. Similar quit rates to gum or patch have been obtained. Data on all NRT, especially newer forms, are limited with regard to seriously ill individuals and among youth, pregnant women, and breastfeeding women. Careful consideration should precede recommendation of NRT in such populations. Knowledgeable clinicians and other appropriately trained practitioners who disclose additional information and concerns may find these vulnerable tobacco users highly compelled and cooperative in requesting, administering, and monitoring these therapies. It is suggested for anyone receiving NRT that all tobacco use be scrupulously avoided to prevent inciting frank nicotine toxicity.
Non-nicotine Pharmacological Therapy
In 1996, the prescription antidepressant buproprion (Wellbutrin®, Zybant>') achieved status as the first nonnicotine pharmacologic therapy approved by the FDA in the treatment of tobacco dependence. It remains the only non-nicotine product that has achieved designation as a first line agent. It is effective in many of the populations in which it has been tested, including those without depression. The proposed mechanism of action of buproprion in the brain is via increased release of dopamine and norepinephrine. When buproprion is used for the suggested 7 to 12 weeks (including the 1 to 2 weeks before quitting tobacco), the abstinence rate doubles over the control (Fiore, 2000) . Clonidine, an antihypertensive, and the tricyclic antidepressant nortriptyline are also indicated for use when prescribed for nicotine addiction, yielding estimated odds ratios of abstinence of 2.1 and 3.2, respectively. Neither agent has received FDA approval for treatment of nicotine dependency. Because of somewhat greater side effects, they are considered second line therapies in the recent AHRQ update (Fiore, 2000) .
Unapproved Treatment Methods
Various success rates have been reported in the literature for the following: hypnosis, acupuncture, herbal remedies, and silver nitrate lozenges. None have been shown to outperform control or placebo treatments using 256 the criteria of AHRQ (Fiore, 2000) . Thus, these methods are not discussed in more detail here. Rapid smoking, a form of aversive conditioning, leads to favorable quit ratios but unacceptably high nicotine levels. It has fallen into disfavor since the advent of pharmacotherapy.
Educational, Counseling, and Treatment Resources
A variety of self help materials, including newsletters, pamphlets, books, tapes, software, and Internet resources, are available to assist in treatment of nicotine addiction. However, the value of such materials has been brought into question. Several pamphlets and books deal specifically with weight gain accompanying tobacco abstinence. Individual counseling by trained therapists is recognized by AHRQ (Fiore, 2000) as a significant benefit to the tobacco user. The American Cancer Society (ACS) Fresh Start" program and the ALA Freedom From Smoking" program are among the most widely available offerings for use in various community settings and consist of multisession group behavioral modification techniques. Modified versions of the ACS program have been employed with teens, expectant mothers, and new mothers. The ALA program has been adapted for use during pregnancy as an online version offered via the Internet, and as a comprehensive self help book.
Professional associations of health care providers, as well as hospitals, universities, churches, corporations, wellness consultants, and other nonprofit agencies, also offer treatment materials or organized programs to assist in tobacco cessation. An Internet based online program for worksite recruitment is in the testing phases. The American Heart Association Heart at Work® program includes worksite plans for reducing tobacco use. A federal government web site provides background and information on making workplaces tobacco free. While some programs and materials are free, there may be significant expense associated with others.
Just how individuals, families, and groups, such as community business and industry, gain access to smoking cessation resources remains an important issue. In many cases, newly emerging health care and community partnerships providing treatment of nicotine dependency are used. However, such programs often do not receive sufficient institutional, volunteer, or donor support to provide free or discounted pharmacotherapy. States have begun to provide web sites listing available smoking cessation programs, so local options can be explored readily by employers and others. The extensive web sites of the CDC and the National Cancer Institute are helpful when seeking information about smoking cessation resources tf SWMMAR Tobacco Abuse and its Treatment: Turning Old and New Issues into Opportunities for the Occupational Health Nurse. DeLucia, A.J. AAOHN ]ournaI2001; 49(5), 243-259. and activities with the potential to reduce the financial and health burden of employee smoking.
A key factor for local businesses to consider, especially small to medium sized employers, is whether the de rninimus approach of relying on such partnership efforts will help attain success in tobacco use cessation. Employers must decide, in line with other key financial decisions, whether to make the investment in tobacco cessation initially to reap the rewards later. Small businesses may rely more on free or reduced cost materials and classes, a practice that often completely begs the issue of who pays for pharmacotherapy, thereby failing to offer employees a powerful adjunct in cessation. Beyond providing resources from a nominal cost and questionably effective inventory of self help materials, the financial burden on businesses greatly escalates when proprietary programs are used, employees are given time off to participate, financial incentives to employees are involved, and additional personnel efforts are needed to organize and manage programs, for example.
One caveat to remember is that better success in treating tobacco dependency is achieved in worksites also providing other programming on lifestyle change. Healthy People 2010 objectives (CDC, 2000d) set a target of 75% of worksites to provide a comprehensive employee health promotion program for employees (1999 baseline 34% to 50%, with lower participation found in businesses with fewer than 750 workers) and 75% of employees to participate in work sponsored health promotion programs. The latter represents a 23% improvement from the 1994 baseline of 61% by the end of the decade. Attaining these goals may also greatly impact job related costs of tobacco use if a significant decline in worksite tobacco use is not eventually realized.
CONCLUSION
A bright future awaits those who direct their efforts toward reducing tobacco's impact in society. Scientific advances in the understanding and treatment of nicotine addiction have revolutionized clinical practice and lead to the availability of several effective over the counter and prescription drugs. In combination with effective intensive treatment strategies such as proactive telephone contact, individual counseling, and group counseling, these drugs markedly enhanced tobacco users' success in long term abstinence. Occupational health nurses may choose to use professional or voluntary opportunities to address tobacco use. They should be trained in contemporary behavioral change theories for individuals, such as the Stages of Change Model to best serve their clients.
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Tobacco use is linked to excessive rates of cardiovascular disease, lung disease, and many fatal neoplasms. In the United States it is the number one cause of illness and premature death. Cigarettes and other combusted forms of tobacco generate environmental tobacco smoke, a major contributor to asthma attacks, heart attacks, and lung cancer among nonsmokers.
Cigarettes are the most prevalent and abused form of tobacco, but other forms, such as cigars and smokeless tobacco, also contain nicotine and may cause dependency in high risk groups that consume these products.
The addictiveness of tobacco products, especially cigarettes, is particularly detrimental to vulnerable groups such as youth, women, blue collar workers, and other high risk and economically disadvantaged populations.
Effective treatment programs (e.g., individual and group counseling, close monitoring, drug treatment) are available to treat nicotine dependency, but many health care providers have been reluctant to educate their patients and clients about these programs.
Workplace tobacco use treatment programs, along with policies to restrict tobacco use, have special merit for employers concerned with worker health and safety, productivity, and profitability.Even the more successful tobacco treatment programs perform better when combined with additional efforts to reduce worker health risks and promote well being.
Many issues converge on the workplace, such as restricting ETS exposure, economic and efficiency benefits, health and wellness improvement, and treatment of substance abuse. While these are obvious and pressing areas where past efforts have been worthwhile, the increasing diversity of the workplace will put emphasis on including age, gender, education, and culture as factors when appropriately tailoring interventions. Occupational nurses are well suited to meet and exceed the expectations of society as it strives to become tobacco free.
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